A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

Official title

An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 2 to < 12 Years) With Fabry Disease and Amenable GLA Variants

Overview

An open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric subjects 2 to \< 12 years of age with Fabry disease and with amenable GLA variants.

Detailed description

This is a Phase 3b, 2-stage, open-label, uncontrolled, multicenter study to evaluate the safety, PK, PD, and efficacy of 12 months of migalastat treatment in pediatric subjects 2 to \< 12 years of age with Fabry disease and with amenable GLA variants. Subjects must be either naïve to enzyme replacement therapy (ERT) or have stopped ERT at least 14 days before Baseline visit.

The study will consist of 2 treatment stages followed by an open-label extension (OLE). Stage 1 will be a treatment period of approximately 3 months (12 weeks); Stage 2 will be a treatment period of 9 months. There will be no break in treatment between Stages 1 and 2. There will be a 30-day (untreated) safety follow-up period for subjects who discontinue treatment at any time.

Subjects will be randomly assigned 1:1:1 to 1 of 3 PK sampling groups using interactive response technology (IRT). Four blood samples for the determination of migalastat concentrations in plasma will be collected in one 24-hour period between Day 15 and Day 30 and at Month 6, and 1 PK (trough) sample will be collected at Month 6 and again at Month 12.

Interventions

• Drug Migalastat HCl 20 mg
  Migalastat will be supplied as 20-mg dispersible tablets. Migalastat 20-mg dispersible tablets contain 16 mg migalastat free base.

Primary outcome measures

• Safety: Incidence of TEAEs, SAEs, and AEs leading to discontinuation of study drug [Time frame: Day 1 (after dosing) through Month 12 and follow-up (30 days after last dose)]
• Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Migalastat [Time frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12]
• Pharmacokinetics (PK): Minimum Observed Plasma Concentration (Cmin) of Migalastat [Time frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12]
• Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve Over The Dosing Interval (AUCtau) of Migalastat [Time frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12]

Secondary outcome measures (9)

• Pharmacodynamic: Change in plasma levels of lyso-Gb3 and its analogs from baseline [Time frame: Baseline to Months 3, 6, and 12/ET]
• Efficacy: Change in eGFR from baseline [Time frame: Baseline to Months 1, 3, 6, and 12/ET]
• Efficacy: Change in urine protein and albumin/microalbumin levels from baseline [Time frame: Baseline to Months 3, 6, and 12/ET]
• Efficacy: Change in Left Ventricular Mass Index (LVMi) from baseline [Time frame: Baseline to Month 12/ET]
• Efficacy: Change in FABPRO-GI And Pain Scores from baseline [Time frame: Baseline to Month 12/ET]
• Efficacy: Mean Patient's Global Impression Of Change (PGI-C) values [Time frame: Months 3, 6, and 12/ET]
• Efficacy: Change in EQ-5D-Y scores from baseline (subjects aged ≥4 years) [Time frame: Baseline to Month 12/ET]
• Efficacy: Change in PedsQL scores from baseline [Time frame: Baseline to Month 12/ET]
• Efficacy: Change in FPHPQ scores from baseline (subjects aged ≥4 years) [Time frame: Baseline to Month 12/ET]

Eligibility criteria

Inclusion criteria

• Male or female subjects, diagnosed with Fabry disease who are between ages 2 and < 12 years at randomization (subjects aged 11 years must have birthdays > 30 days after randomization)
• Subject's parent or legally authorized representative is willing and able to provide written informed consent and authorization for use and disclosure of personal health information or research-related health information, and subject provides assent, if applicable.
• Subject has a GLA variant documented in his/her medical record that is amenable to migalastat prior to Visit 2.
• Subject has not received ERT (eg, Replagal® \[agalsidase alfa\] or Fabrazyme® \[agalsidase beta\]) for at least 14 days prior to Baseline visit.
• Subject has at least 1 documented complication (ie, historical or current laboratory abnormality or sign/symptom) of Fabry disease
• If of reproductive potential, both male and female subjects agree to use a medically accepted method of contraception throughout the duration of the study and for up to 30 days after their last dose of migalastat.

Exclusion criteria

• Has moderate or severe renal impairment (eGFR < 60 mL/min/1.73 m2 at Visit 1 \[screening\]).
• Has advanced kidney disease requiring dialysis or kidney transplantation.
• History of allergy or sensitivity to migalastat (including excipients) or other iminosugars (eg, miglustat, miglitol).
• Has received any investigational/experimental drug, biologic, or device within 30 days or 5 half-lives of the investigational product (whichever is longer) before Visit 1 (screening).
• Has received any gene therapy at any time or anticipates starting gene therapy during the study period.
• Requires treatment with Glyset (miglitol) or Zavesca (miglustat), within 6 months before Visit 1(screening) or throughout the study.
• Has any intercurrent illness or condition at Visit 1 (screening) or Visit 2 (baseline) that may preclude the subject from fulfilling the protocol requirements or suggests to the investigator that the potential subject may have an unacceptable risk by participating in this study.
• Pregnant or breastfeeding
• Otherwise unsuitable for the study in the opinion of the investigator

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 6 centers

• Emory Genetics — Atlanta
• University of Minnesota Masonic Children's Hospital — Minneapolis
• Atrium Health Levine Children's Hospital — Charlotte
• Cincinnati Children's Hospital Medical Center — Cincinnati
• UPMC Children's Hospital of Pittsburgh — Pittsburgh
• Lysosomal and Rare Disorders Research and Treatment Center, Inc. — Fairfax

United Kingdom · 2 centers

• Great Ormond Street Hospital for Children NHS Foundation Trust — London
• Manchester University NHS Foundation Trust — Manchester

Belgium · 1 center

• Universitair Ziekenhuis (UZ) Leuven — Leuven

Germany · 1 center

• Universitäetsklinikum Müenster (UKM) Klinik für Kinder- und Jugendmedizin - Allgemeine Pae — Münster

Spain · 1 center

• Hospital Universitario de la Paz — Madrid

Identifiers

NCT: NCT06904261 · AT1001-033

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗